Ubs Asset Management Americas Inc Krystal Biotech, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 251,762 shares of KRYS stock, worth $44.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
251,762
Previous 18,261
1278.69%
Holding current value
$44.5 Million
Previous $3.25 Million
1322.99%
% of portfolio
0.01%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KRYS
# of Institutions
275Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$698 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$430 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$236 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$181 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.54B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...